Altimmune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 6, 2024

Rhea-AI Summary

Altimmune, Inc. (Nasdaq: ALT) announced an abstract on pemvidutide in subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease will be presented at the NASH-TAG Conference. Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and MASH. The presentation will discuss the correlation between Pemvidutide-induced liver fat reduction and improvements in non-invasive markers of inflammation and fibrosis.

GAITHERSBURG, Md., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced an abstract on pemvidutide in subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease¹ will be presented at the NASH-TAG Conference, which will be held in Park City, UT on January 4-6, 2024. Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and MASH². Details for the presentation are as follows:

Title:	Pemvidutide-Induced Liver Fat Reduction in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease Correlates with Improvements in Non-Invasive Markers of Inflammation and Fibrosis: Results of a 24-week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (abstract #51)
Authors:	Stephen A. Harrison, Shaheen Tomah, John J. Suschak, Jonathan Kasper, M. Scot Roberts, M. Scott Harris, Sarah K. Browne
Date:	Saturday, January 6, 2024

A copy of the abstract will be accessible on the Events section of the Altimmune website.

¹previously termed Non-Alcoholic Fatty Liver Disease
² previously termed NASH

About Altimmune 
Altimmune is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and MASH, formerly known as NASH. In addition, Altimmune is developing HepTcell^™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Investor Contact:
Rich Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
reisenstadt@altimmune.com

Media Contact:
Danielle Cantey
Evoke Canale
Phone: 619-826-4657
danielle.cantey@evokegroup.com

FAQ

What is the name of the company mentioned in the press release and its ticker symbol?

Altimmune, Inc. (Nasdaq: ALT) is the company mentioned in the press release with the ticker symbol ALT.

What is the abstract about?

The abstract is about pemvidutide in subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease, discussing its correlation with improvements in non-invasive markers of inflammation and fibrosis.

What is pemvidutide?

Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and MASH.

When and where will the presentation take place?

The presentation will take place at the NASH-TAG Conference in Park City, UT on January 4-6, 2024.

Who are the authors of the abstract?

The authors of the abstract are Stephen A. Harrison, Shaheen Tomah, John J. Suschak, Jonathan Kasper, M. Scot Roberts, M. Scott Harris, and Sarah K. Browne.

Where can a copy of the abstract be accessed?

A copy of the abstract will be accessible on the Events section of the Altimmune website.